The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) TRULANCE, a treatment for adults with chronic idiopathic constipation, does not have a side-effect profile superior to its competitors, specifically with regard to the side effect of diarrhea, and (2) Synergy was unable to meet certain undisclosed loan agreement conditions requiring the Company to have $128 million in cash or cash equivalents by Januto obtain $100 million (“CRG Loan”) in financing for TRULANCE without issuing shares and diluting shareholders. Synergy Pharmaceuticals, Inc., et al., No. District Court for the Eastern District of New York on behalf of all those who purchased Synergy securities listed on the NASDAQ or domestically in the United States between Novemand November 12, 2017, inclusive (the “Class Period”). The lawsuit expanding the class period has been filed in the U.S. The deadline to seek the role of lead plaintiff in the class action is April 10, 2018. (“Synergy” or the “Company”) (NASDAQ:SGYP) and certain of its officers. With Expanded Class Periodįaruqi & Faruqi, LLP, a leading national securities law firm, has filed a federal securities class action complaint against Synergy Pharmaceuticals, Inc. Faruqi & Faruqi, LLP Files Securities Fraud Class Action Complaint Against Synergy Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |